PriceTargets.com logo

Axcella Health - AXLA Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $50.00
  • Forecasted Upside: 4,639.34%
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$1.06 As of 12/1/2023 01:00 AM ET
▲ +0.07 (7.11%)

This chart shows the closing price for AXLA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Axcella Health Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for AXLA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AXLA

Analyst Price Target is $50.00
▲ +4,639.34% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Axcella Health in the last 3 months. The average price target is $50.00, with a high forecast of $50.00 and a low forecast of $50.00. The average price target represents a 4,639.34% upside from the last price of $1.06.

This chart shows the closing price for AXLA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 2 investment analysts is to hold stock in Axcella Health. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
6/11/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
9/9/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
12/8/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
3/8/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
6/6/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
9/4/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
11/3/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
12/3/2023

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/16/2023HC WainwrightReiterated RatingNeutralLow
12/16/2022SVB LeerinkReiterated RatingOutperform ➝ Market Perform$150.00 ➝ $50.00Low
12/15/2022HC WainwrightDowngradeBuy ➝ NeutralLow
11/2/2022WedbushReiterated RatingOutperform$150.00Low
11/2/2022Chardan CapitalLower TargetBuy$175.00 ➝ $125.00Low
11/2/2022HC WainwrightLower Target$250.00 ➝ $200.00N/A
10/3/2022HC WainwrightBoost TargetBuy$200.00 ➝ $250.00Low
8/3/2022HC WainwrightLower TargetBuy$350.00 ➝ $200.00Low
8/3/2022SVB LeerinkLower TargetOutperform$225.00 ➝ $150.00Low
5/27/2022WedbushLower Target$175.00Medium
5/9/2022Chardan CapitalLower TargetBuy$300.00 ➝ $175.00High
3/31/2022SVB LeerinkLower TargetOutperform$250.00 ➝ $225.00Medium
12/16/2021Roth CapitalReiterated RatingBuyHigh
11/16/2021Chardan CapitalBoost TargetBuy$250.00 ➝ $300.00Low
10/12/2021Noble FinancialInitiated CoverageOutperform$150.00Low
9/22/2021The Goldman Sachs GroupDowngradeBuy ➝ Neutral$225.00 ➝ $125.00Low
7/30/2021SVB LeerinkInitiated CoverageBuy$250.00Medium
7/30/2021Chardan CapitalReiterated RatingBuy$250.00Low
7/30/2021JPMorgan Chase & Co.DowngradeNeutral ➝ UnderweightHigh
7/6/2021HC WainwrightInitiated CoverageBuy$350.00High
6/3/2021Chardan CapitalLower TargetBuy$400.00 ➝ $250.00Low
3/20/2021WedbushReiterated RatingBuy$475.00 ➝ $275.00Low
11/26/2020Chardan CapitalReiterated RatingBuy$400.00Low
11/18/2020Roth CapitalInitiated CoverageBuy$700.00High
10/27/2020Chardan CapitalInitiated CoverageBuy$400.00Medium
10/26/2020SVB LeerinkReiterated RatingOutperform$250.00High
10/14/2020JPMorgan Chase & Co.Initiated CoverageNeutralMedium
9/25/2020B. RileyInitiated CoverageBuy$350.00High
9/24/2020B. RileyReiterated RatingBuyLow
8/27/2020WedbushReiterated RatingBuy$475.00Medium
8/14/2020WedbushReiterated RatingBuy$475.00Medium
8/12/2020The Goldman Sachs GroupReiterated RatingBuy$225.00High
8/6/2020SVB LeerinkLower TargetOutperform$500.00 ➝ $250.00Low
7/30/2020Piper SandlerInitiated CoverageOverweight$625.00High
7/9/2020BTIG ResearchLower TargetBuy$700.00 ➝ $400.00High
5/27/2020WedbushInitiated CoverageOutperform$700.00 ➝ $700.00High
5/18/2020SVB LeerinkLower TargetOutperform$525.00 ➝ $500.00Medium
5/1/2020BTIG ResearchInitiated CoverageBuy$250.00High
6/3/2019SVB LeerinkInitiated CoverageOutperform ➝ Outperform$525.00Low
6/3/2019JPMorgan Chase & Co.Initiated CoverageOverweight ➝ Overweight$500.00High
6/2/2019The Goldman Sachs GroupInitiated CoverageBuy ➝ Buy$625.00High
(Data available from 12/3/2018 forward)

News Sentiment Rating

0.00 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
5/7/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/6/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/6/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/5/2023
  • 1 very positive mentions
  • 5 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
9/4/2023
  • 1 very positive mentions
  • 3 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Mentions as of
10/4/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/3/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/3/2023

Current Sentiment

  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
Axcella Health logo
Axcella Health Inc. operates as a clinical-stage biotechnology company in the United States. The company treats complex diseases using endogenous metabolic modulators. Its product pipeline includes AXA1125 that is in Phase 2a clinical trial for long COVID therapy for patients, as well as Phase 2b clinical trial for treating non-alcoholic steatohepatitis; and AXA1665, which is in Phase 2 clinical trial for the reduction in risk of overt hepatic encephalopathy recurrence. The company was formerly known as Newco LS16, Inc. and changed its name to Axcella Health Inc. in June 2016. Axcella Health Inc. was incorporated in 2008 and is based in Cambridge, Massachusetts.
Read More

Today's Range

Now: $1.06
Low: $0.95
High: $1.20

50 Day Range

MA: $6.65
Low: $1.00
High: $10.65

52 Week Range

Now: $1.06
Low: $0.81
High: $41.25

Volume

46,451 shs

Average Volume

41,720 shs

Market Capitalization

$3.11 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.58

Frequently Asked Questions

What sell-side analysts currently cover shares of Axcella Health?

The following Wall Street analysts have issued stock ratings on Axcella Health in the last year: HC Wainwright, and SVB Leerink LLC.
View the latest analyst ratings for AXLA.

What is the current price target for Axcella Health?

1 Wall Street analysts have set twelve-month price targets for Axcella Health in the last year. Their average twelve-month price target is $50.00, suggesting a possible upside of 4,639.3%. SVB Leerink LLC has the highest price target set, predicting AXLA will reach $50.00 in the next twelve months. SVB Leerink LLC has the lowest price target set, forecasting a price of $50.00 for Axcella Health in the next year.
View the latest price targets for AXLA.

What is the current consensus analyst rating for Axcella Health?

Axcella Health currently has 2 hold ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in AXLA, but not buy more shares or sell existing shares.
View the latest ratings for AXLA.

What other companies compete with Axcella Health?

Other companies that are similar to Axcella Health include Eloxx Pharmaceuticals, TradeUP Acquisition, Fresh Tracks Therapeutics, Windtree Therapeutics and Palisade Bio. Learn More about companies similar to Axcella Health.

How do I contact Axcella Health's investor relations team?

Axcella Health's physical mailing address is 840 MEMORIAL DRIVE, CAMBRIDGE MA, 02139. The company's listed phone number is (857) 320-2200 and its investor relations email address is i[email protected]. The official website for Axcella Health is www.axcellahealth.com. Learn More about contacing Axcella Health investor relations.